<DOC>
	<DOCNO>NCT00003296</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness liposomal doxorubicin treat patient liver bile duct cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Treating Patients With Liver Bile Duct Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate toxicity doxorubicin HCl liposome patient carcinomas liver bile duct . OUTLINE : Patients receive doxorubicin HCl liposome IV 15 minute every 21 day . Filgrastim ( G-CSF ) administer subcutaneously start day 2 continue 10-14 day . Disease restaged every 3 course . Treatment continue absence unacceptable toxicity disease progression . Patients follow every 3 month first year , every 6 month thereafter . PROJECTED ACCRUAL : There 17-26 evaluable patient accrue study .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm carcinoma liver bile duct include hepatocellular carcinoma , cholangiocarcinoma , gallbladder cancer Measurable evaluable disease CT scan ( ascites , pleural effusion , bone metastasis consider evaluable ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 3 mg/dL No severe cirrhosis Renal : Creatinine great 3.0 mg/dL Cardiovascular : Left ventricular cardiac ejection fraction least 45 % Other : No allergy egg egg product Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior doxorubicin At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2000</verification_date>
	<keyword>localize resectable adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>localize gallbladder cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>localize extrahepatic bile duct cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>cholangiocarcinoma gallbladder</keyword>
	<keyword>cholangiocarcinoma extrahepatic bile duct</keyword>
	<keyword>adult primary cholangiocellular carcinoma</keyword>
</DOC>